Zlateva G - Search Results

1

Burden of illness of neovascular age-related macular degeneration in Canada.

Cruess A, Zlateva G, Xu X, Rochon S. Cruess A, et al. Among authors: zlateva g. Can J Ophthalmol. 2007 Dec;42(6):836-43. doi: 10.3129/i07-153. Can J Ophthalmol. 2007. PMID: 18026200

2

The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.

Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. Chandran A, et al. Among authors: zlateva g. J Manag Care Pharm. 2012 Jul-Aug;18(6):415-26. doi: 10.18553/jmcp.2012.18.6.415. J Manag Care Pharm. 2012. PMID: 22839682

3

Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains.

Perrot S, Schaefer C, Knight T, Hufstader M, Chandran AB, Zlateva G. Perrot S, et al. Among authors: zlateva g. BMC Musculoskelet Disord. 2012 Feb 17;13:22. doi: 10.1186/1471-2474-13-22. BMC Musculoskelet Disord. 2012. PMID: 22340435 Free PMC article.

4

Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.

Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Chakravarthy U, et al. Among authors: zlateva g. BMC Ophthalmol. 2010 Dec 13;10:31. doi: 10.1186/1471-2415-10-31. BMC Ophthalmol. 2010. PMID: 21144031 Free PMC article. Review.

5

Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

Levy AR, Szabo S, Briggs A, Pleil A, Davie A, Zlateva G, Javitt J. Levy AR, et al. Among authors: zlateva g. J Ophthalmol. 2009;2009:540431. doi: 10.1155/2009/540431. Epub 2010 Feb 16. J Ophthalmol. 2009. PMID: 20339464 Free PMC article.

6

Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study.

Weber PA, Wirostko BM, Xu X, Goss TF, Zlateva G. Weber PA, et al. Among authors: zlateva g. BMC Ophthalmol. 2010 Feb 9;10:2. doi: 10.1186/1471-2415-10-2. BMC Ophthalmol. 2010. PMID: 20144224 Free PMC article.

7

Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties.

Cruess AF, Zlateva G, Pleil AM, Wirostko B. Cruess AF, et al. Among authors: zlateva g. Acta Ophthalmol. 2009 Mar;87(2):118-32. doi: 10.1111/j.1755-3768.2008.01218.x. Epub 2008 Jun 13. Acta Ophthalmol. 2009. PMID: 18577193 Review.

8

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G. Ruiz-Moreno JM, et al. Among authors: zlateva g. Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300. Epub 2008 Jun 10. Curr Med Res Opin. 2008. PMID: 18547463

9

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF. Cruess AF, et al. Among authors: zlateva g. Pharmacoeconomics. 2008;26(1):57-73. doi: 10.2165/00019053-200826010-00006. Pharmacoeconomics. 2008. PMID: 18088159

10

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. Wong TY, et al. Among authors: zlateva g. Ophthalmology. 2008 Jan;115(1):116-26. doi: 10.1016/j.ophtha.2007.03.008. Epub 2007 Aug 6. Ophthalmology. 2008. PMID: 17675159 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results